Prostate Conditions Education Council & Janssen Biotech
Janssen Biotech, Inc. is sponsoring an advanced prostate cancer research study. This study will evaluate the effectiveness of an investigational drug plus prednisone to determine if there is a decrease in Prostate-Specific Antigen (PSA).
The study will also evaluate whether this combination prolongs the time until it is evident that the cancer has spread. Additionally, safety information will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last. You may be eligible for the study if you:
- Are eighteen years of age or older
- Have been diagnosed with prostate cancer
- Are currently receiving, and have had continuous therapy with, Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months or have undergone surgical removal of the testicles
To learn more about this study, please visit www.prostatecancerstudynow.com